keyword
MENU ▼
Read by QxMD icon Read
search

AL amyloidosis treatment

keyword
https://www.readbyqxmd.com/read/30400895/renal-limited-al-amyloidosis-a-diagnostic-and-management-dilemma
#1
Kar Wah Fuah, Christopher Thiam Seong Lim
BACKGROUND: Amyloidosis is a disorder caused by extracellular tissue deposition of insoluble fibrils which may result in a wide spectrum of symptoms depending upon their types, sites and amount of deposition. Amyloidosis can be divided into either systemic or localized disease. CASE PRESENTATION: We present a case of a middle-aged gentleman who presented with persistent nephrotic syndrome with worsening renal function. Repeated renal biopsies showed the presence of renal-limited AL amyloidosis...
November 6, 2018: BMC Nephrology
https://www.readbyqxmd.com/read/30381502/clinical-and-laboratory-profile-of-renal-amyloidosis-a-single-center-experience
#2
Divyesh P Engineer, Vivek B Kute, Himanshu V Patel, Pankaj R Shah
The kidney is the most common organ involved in systemic amyloidosis. We aimed to study etiology and clinicopathological profile of renal amyloidosis. This was a retrospective study of 40 consecutive adult patients with biopsy-proven renal amyloidosis evaluated over a period of two years. Emphasis was given to describing the clinical presentation, renal function, proteinuria, type of amyloidosis, and its etiology. Mean age of the study cohort was 44 ± 15 years (with a male-to-female ratio of 3:1). Amyloid A (AA) amyloidosis was the most common type of amyloidosis observed in 72...
September 2018: Saudi Journal of Kidney Diseases and Transplantation
https://www.readbyqxmd.com/read/30354284/mortality-and-healthcare-costs-in-medicare-beneficiaries-with-al-amyloidosis
#3
Tiffany P Quock, Eunice Chang, Jennifer S Munday, Sohum Gokhale, Tingjian Yan
AIMS: Examine mortality and healthcare costs in Medicare beneficiaries with newly diagnosed immunoglobulin light chain (AL) amyloidosis. PATIENTS & METHODS: Cases were identified in 2012-2015 Medicare 5% data with ≥1 inpatient/≥2 outpatient claims consistent with AL amyloidosis and ≥1 AL-specific treatment. Cases were matched 3:1 with disease-free controls. Descriptive statistics were reported. RESULTS:  A total of 249 (33.3%) cases were matched to 747 (66...
October 25, 2018: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/30344985/acquired-factor-vii-deficiency-causing-severe-bleeding-disorder-secondary-to-al-amyloidosis-of-the-liver
#4
Anthony L Nguyen, Muhammad Kamal, Ravi Raghavan, Gayathri Nagaraj
A 52 year-old male presented with neck pain after undergoing thyroidectomy for a goiter three weeks prior which was complicated by a neck hematoma requiring evacuation. Computed tomography (CT) scan showed a neck hematoma requiring evacuation and he received desmopressin with cessation of bleeding. Coagulation studies were normal. He returned eighteen months later with severe oral mucosal bleeding after a dental procedure and required transfusions with red blood cells, platelets, and fresh frozen plasma (FFP) in addition to desmopressin, Humate-P, aminocaproic acid, and surgical packing...
September 5, 2018: Hematology Reports
https://www.readbyqxmd.com/read/30344148/dysphagia-unveiling-systemic-immunoglobulin-light-chain-amyloidosis-with-multiple-myeloma
#5
Juan Gonzalez, Ahsan Wahab, Kavitha Kesari
Dysphagia is an uncommon presentation of systemic immunoglobulin light-chain (AL) amyloidosis with multiple myeloma (MM). Gastrointestinal (GI) involvement usually manifests with altered motility, malabsorption or bleeding. Furthermore, patients identified with GI amyloidosis, without previous diagnosis of a plasma cell disorder, are extremely rare. We report an elderly woman who presented with acute on chronic cardiac dysfunction, sick sinus syndrome and acute renal failure. While admitted, she developed intermittent dysphagia to both solids and liquids...
October 21, 2018: BMJ Case Reports
https://www.readbyqxmd.com/read/30299492/al-amyloidosis-advances-in-diagnostics-and-treatment
#6
Romana Ryšavá
AL amyloidosis (light chain; previously also called primary amyloidosis) is a systemic disease characterized by an amyloid deposition process affecting many organs, and which still has unsatisfactory survival of patients. The monoclonal light chains kappa (κ) or lambda (λ) or their fragments form the fibrils that deposit and accumulate in different tissues. Renal involvement is very frequent in AL amyloidosis and can lead to the development of nephrotic syndrome followed by renal failure in some cases. AL amyloidosis ultimately leads to destruction of tissues and progressive disease...
October 8, 2018: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/30261180/cutaneous-light-chain-amyloidosis-with-multiple-myeloma-a-concise-review
#7
REVIEW
Mirela Andrei, Jen Chin Wang
OBJECTIVE/BACKGROUND: Cutaneous immunoglobulin (Ig) amyloid light-chain (AL) amyloidosis associated with overt multiple myeloma (MM) is rare and optimal treatment is not well defined. The recently developed highly efficacious MM therapy has brought on a new set of challenges to this field for consideration. The goal of this paper is to describe the characteristics of cutaneous manifestations of systemic AL amyloidosis associated with MM according to age, sex, race, Ig type, plasma cell percentage, and cytogenetic and fluorescent in situ hybridization studies along with their outcomes...
September 21, 2018: Hematology/oncology and Stem Cell Therapy
https://www.readbyqxmd.com/read/30232705/chronic-intestinal-pseudo-obstruction-due-to-al-amyloidosis-a-case-report-and-literature-review
#8
Tomoya Iida, Daisuke Hirayama, Gota Sudo, Kei Mitsuhashi, Hisayoshi Igarashi, Kentaro Yamashita, Hiroo Yamano, Hiroshi Nakase
A 59-year-old woman presented to our hospital with a 6-month history of nausea, weight loss, and abdominal distension. Physical examination revealed abdominal distension without tenderness, and edema, numbness, and multiple peripheral neuropathy in the limbs. Blood test results showed anemia, hypoproteinemia, and hypoalbuminemia. Immunoelectrophoresis detected kappa-type Bence-Jones protein in both the serum and urine. Bone marrow examination did not reveal an increase of plasma cells. Computed tomography showed intestinal distension and retention of intestinal contents...
September 19, 2018: Clinical Journal of Gastroenterology
https://www.readbyqxmd.com/read/30228867/recent-advances-in-understanding-and-treating-immunoglobulin-light-chain-amyloidosis
#9
REVIEW
Talha Badar, Anita D'Souza, Parameswaran Hari
Immunoglobulin (Ig) light chain (AL) amyloidosis is a clonal plasma cell disorder characterized by misfolded Ig light chain deposition in vital organs of the body, resulting in proteotoxicity and organ dysfunction. Owing to its diverse clinical presentations and a tendency to mimic common medical conditions, AL amyloidosis is often diagnosed late and results in dismal outcomes. Early referral to a specialized center with expertise in management of AL amyloidosis is always recommended. The availability of sensitive biomarkers and novel therapies is reforming our approach to how we manage AL amyloidosis...
2018: F1000Research
https://www.readbyqxmd.com/read/30223349/therapies-for-cardiac-light-chain-amyloidosis-an-update
#10
Alberto Aimo, Gabriele Buda, Marianna Fontana, Andrea Barison, Giuseppe Vergaro, Michele Emdin, Giampaolo Merlini
Light-chain (AL) amyloidosis is the most common type of systemic amyloidosis, affecting around 10 people per million per year. This serious disorder is characterized by the presence of a clone of bone marrow plasma cells that produces monoclonal light chains (LCs) of the κ or predominantly λ type. These amyloidogenic LCs undergo extracellular misfolding and aggregation into proteotoxic soluble oligomers and amyloid fibrils that deposit within tissues. The lethal consequences of AL amyloidosis are due to the toxic products (the LCs) and not to the malignant behaviour of the plasma cell clone...
November 15, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/30169860/the-clinical-implication-of-monoclonal-gammopathies-monoclonal-gammopathy-of-undetermined-significance-and-monoclonal-gammopathy-of-renal-significance
#11
Krzysztof Batko, Jolanta Malyszko, Artur Jurczyszyn, David H Vesole, Morie A Gertz, Xavier Leleu, Anna Suska, Marcin Krzanowski, Wladyslaw Sulowicz, Jacek S Malyszko, Katarzyna Krzanowska
Monoclonal gammopathy of renal significance (MGRS) has introduced a new perspective to several well-known disease entities impacting nephrology, haematology and pathology. Given the constantly changing disease spectrum of these entities, it is clinically imperative to establish diagnostic and treatment pathways supported by evidence-based medicine. MGRS is a disease of the kidney, secondary to plasma cell clonal proliferation or immune dysfunction, requiring therapeutic intervention to eradicate the offending clone...
August 28, 2018: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/30108642/trifascicular-block-as-primary-presentation-of-the-cardiac-amyloidosis-a-rare-case-report
#12
Mohsen Yaghubi, Hossein Dinpanah, Fahimeh Ghanei-Motlagh, Samaneh Kakhki, Reza Ghasemi
BACKGROUND: Amyloidosis is a severe systemic disorder produces by the accumulation of inappropriately amyloid deposition in tissues. Cardiac involvement, as a main type of amyloidosis, has a major impact on prognosis. We describe a biopsy-proven cardiac amyloidosis in an old man with unexpected presentation. CASE REPORT: A 70-year-old man, with a complaint of severe weakness, lightheadedness, and lower limb paresthesia, was admitted to the emergency department. Electrocardiography revealed right bundle branch block and Trifascicular block...
March 2018: ARYA Atherosclerosis
https://www.readbyqxmd.com/read/30108065/treatment-of-al-amyloidosis-with-bendamustine-a-study-of-122-patients
#13
LETTER
Paolo Milani, Stefan Schönland, Giampaolo Merlini, Christoph Kimmich, Andrea Foli, Tobias Dittrich, Marco Basset, Carsten Müller-Tidow, Tilmann Bochtler, Giovanni Palladini, Ute Hegenbart
No abstract text is available yet for this article.
November 1, 2018: Blood
https://www.readbyqxmd.com/read/30101047/portal-hypertension-and-a-stiff-liver
#14
Felicia D'Alitto, Amina Scherz, Cristina Margini, Hendrik Von Tengg-Kobligk, Matteo Montani, Thomas Pabst, Annalisa Berzigotti
Portal hypertension (PH) is a common clinical syndrome leading to severe complications. In the western world, about 90% of cases of PH are due to liver cirrhosis, and thanks to the availability of ultrasound elastography methods, this diagnosis is usually confirmed at bedside. We report a case of a patient presenting with PH and ascites initially suspected of suffering from liver cirrhosis. The finding of large hepatomegaly and a massive increase in liver stiffness prompted us to perform a liver biopsy. This revealed no fibrosis, but diffuse primary amyloidosis (AL amyloidosis)...
June 8, 2018: Curēus
https://www.readbyqxmd.com/read/30095161/real-world-outcomes-of-pomalidomide-for-treatment-of-relapsed-light-chain-amyloidosis
#15
Faye A Sharpley, Richa Manwani, Shameem Mahmood, Sajitha Sachchithanantham, Helen Lachmann, Julian Gilmore, Carol Whelan, Phillip Hawkins, Ashutosh Wechalekar
Pomalidomide is a next-generation immunomodulatory agent with activity in relapsed light chain (AL) amyloidosis, but real world outcomes are lacking. We report the experience of the UK National Amyloidosis Centre. All patients with AL amyloidosis treated with pomalidomide between 2009 and 2017 were included. Data was collected on treatment toxicity and clonal response. Survival was calculated by the Kaplan-Meier method and outcomes reported on an intent-to-treat (ITT) basis. A total of 29 patients treated with pomalidomide were identified...
August 10, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/30079070/cd38-as-immunotherapeutic-target-in-light-chain-amyloidosis-and-multiple-myeloma-association-with-molecular-entities-risk-survival-and-mechanisms-of-upfront-resistance
#16
Anja Seckinger, Jens Hillengass, Martina Emde, Susanne Beck, Christoph Kimmich, Tobias Dittrich, Michael Hundemer, Anna Jauch, Ute Hegenbart, Marc-Steffen Raab, Anthony D Ho, Stefan Schönland, Dirk Hose
Monoclonal antibodies against the cell surface antigen CD38, e.g., isatuximab, daratumumab, or Mor202, have entered the therapeutic armamentarium in multiple myeloma due to single agent overall response rates of 29 vs. 36 vs. 31%, effectivity in combination regimen, e.g., with lenalidomide or bortezomib plus dexamethasone, and tolerable side effects. Despite clinical use, many questions remain. In this manuscript, we address three of these: first, upfront CD38 target-expression in AL-amyloidosis, monoclonal gammopathy of unknown significance (MGUS), asymptomatic, symptomatic, and relapsed multiple myeloma...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/30049825/cardiovascular-adverse-events-in-modern-myeloma-therapy-incidence-and-risks-a-review-from-the-european-myeloma-network-emn-and-italian-society-of-arterial-hypertension-siia
#17
REVIEW
Sara Bringhen, Alberto Milan, Claudio Ferri, Ralph Wäsch, Francesca Gay, Alessandra Larocca, Marco Salvini, Evangelos Terpos, Hartmut Goldschmidt, Michele Cavo, Maria Teresa Petrucci, Heinz Ludwig, Holger W Auner, Jo Caers, Martin Gramatzki, Mario Boccadoro, Hermann Einsele, Pieter Sonneveld, Monika Engelhardt
Cardiovascular disease in patients with multiple myeloma may derive from factors unrelated to the disease (age, diabetes, dyslipidemia, obesity, prior cardiovascular diseases), related to the disease (cardiac AL-amyloidosis, hyperviscosity, high-output failure, arteriovenous shunting, anemia, renal dysfunction) and/or related to anti-myeloma treatment (anthracyclines, corticosteroids, alkylating agents, immunomodulatory drugs, proteasome inhibitors). Good knowledge of cardiovascular events, effective dose reductions, prevention and management of early and late cardiovascular side effects of chemotherapeutic agents are essential in current clinical practice...
September 2018: Haematologica
https://www.readbyqxmd.com/read/30042220/al-amyloidosis-presenting-with-limb-girdle-myopathy
#18
Naveed Malek, Dominic G O'Donovan, Hadi Manji
An elderly Caucasian man presented with a 10-month history of proximal myopathy and dysphagia. His serum creatine kinase (CK) was elevated at 877 U/L (normal 40-320) and electromyography confirmed a myopathic process. Blood and urine tests suggested myeloma; bone marrow examination showed 30% plasma cells and stained positive for amyloid. The muscle biopsy was initially reported as normal but in the light of the bone marrow report, the biopsy specimen was stained for amyloid, which was positive. We diagnosed systemic amyloidosis causing a myopathy and have started treatment for myeloma...
July 24, 2018: Practical Neurology
https://www.readbyqxmd.com/read/30040145/immunoglobulin-light-chain-amyloidosis-2018-update-on-diagnosis-prognosis-and-treatment
#19
Morie A Gertz
DISEASE OVERVIEW: Immunoglobulin light chain amyloidosis is a clonal, nonproliferative plasma cell disorder in which fragments of immunoglobulin light or heavy chain are deposited in tissues. Clinical features depend on organs involved but can include restrictive cardiomyopathy, nephrotic syndrome, hepatic dysfunction, peripheral/autonomic neuropathy, and "atypical multiple myeloma." DIAGNOSIS: Tissue biopsy stained with Congo red demonstrating amyloid deposits with apple-green birefringence is required for diagnosis...
September 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30038381/european-myeloma-network-recommendations-on-diagnosis-and-management-of-patients-with-rare-plasma-cell-dyscrasias
#20
REVIEW
Maria Gavriatopoulou, Pellegrino Musto, Jo Caers, Giampaolo Merlini, Efstathios Kastritis, Niels van de Donk, Francesca Gay, Ute Hegenbart, Roman Hajek, Sonja Zweegman, Benedetto Bruno, Christian Straka, Meletios A Dimopoulos, Hermann Einsele, Mario Boccadoro, Pieter Sonneveld, Monika Engelhardt, Evangelos Terpos
The introduction of novel agents in the management of multiple myeloma and related plasma cell dyscrasias has changed our treatment approaches and subsequently the outcome of patients. Due to current advances, the European Myeloma Network updated the diagnostic and therapeutic recommendations for patients with Waldenström's macroglobulinemia (WM), AL-amyloidosis, monoclonal immunoglobulin deposition disease (MIDD), POEMS syndrome, and primary plasma cell leukemia. For patients with WM, the combination of rituximab with chemotherapy remains the treatment cornerstone, while the Bruton-tyrosine kinase inhibitor ibrutinib has been introduced and approved for relapsed/refractory disease...
September 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
keyword
keyword
108682
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"